Drug intelligence / Profile preview

GKIND003A

Development stage: Preclinical
Lead developer: China Resources Guokang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

GKIND003A is a small molecule inhibitor targeting Neurotrophic Tyrosine Receptor Kinase (NTRK), currently under development by China Resources Guokang Pharmaceutical. It is specifically designed for the treatment of solid tumors harboring NTRK gene fusions, a genomic alteration that drives constitutive kinase activity and promotes tumor cell survival and proliferation. The drug is currently in the IND-enabling (Pre-IND) stage of development, aiming to provide a targeted therapeutic option for patients with TRK-fusion positive cancers.

Targets

Trk (Trk receptor family)

Beyond the preview

Go deeper on GKIND003A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GKIND003A.

Explore the full profile